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Abstract Immunoglobulin (Ig) A nephropathy is the
most common type of glomerulonephritis worldwide. Data
on its natural history suggest that approximately 40% of
patients progress to end-stage renal failure after 20 years.
Various therapies such as antiplatelet medication, ﬁsh oil,
oral prednisolone, intravenous prednisolone, tonsillectomy,
and tonsillectomy plus steroid pulse (TSP) have been
proposed. Japanese nephrologists face challenging issues
regarding this disease, such as the usefulness of the annual
urinary screening system (kenshin) and kidney biopsies,
the desire of patients and their families for treatment
despite insufﬁcient clinical evidence, and the risk of
overtreatment with TSP versus the loss of a ‘golden period’
with late intervention. We review the current literature on
tonsillectomy, steroid therapy, and TSP, which was ﬁrst
proposed in Japan, and present some perspectives on the
treatment of IgA nephropathy.
Keywords IgA nephropathy  Steroid therapy 
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Introduction
More than 40 years have passed since immunoglobulin (Ig)
A nephropathy was ﬁrst described by Berger and Hinglais
in 1968 [1]. Various approaches such as antiplatelet med-
ication, ﬁsh oil, oral prednisolone, intravenous predniso-
lone, tonsillectomy, and tonsillectomy plus steroid pulse
therapy (TSP), have been proposed for treating patients
with adult IgA nephropathy. Clinicians often face chal-
lenges in deciding which treatment is most suitable for
each patient, while balancing the hopes of patients and
their families with insufﬁcient clinical evidence. Here we
review the data from clinical trials and give a perspective
on the treatment of IgA nephropathy.
What is the treatment dilemma for Japanese
nephrologists?
Are the annual urinary screening system (kenshin)
and kidney biopsies useful?
A Japanese law established a system of annual urinary
screening (kenshin) in schools and workplaces approxi-
mately 40 years ago. About 40% of the Japanese popula-
tion receive kenshin each year. Persons with detected
urinary abnormalities are advised to consult local physi-
cians. If a local physician ﬁnds[1? proteinuria on repeat
urinary testing, he refers the patient to a nephrologist.
Approximately 10,000 kidney biopsies are performed each
year in Japan, of which 30–40% (3,000–4,000 persons)
receive a diagnosis of IgA nephropathy. Many patients
with IgA nephropathy are diagnosed at an early stage in
Japan. The beneﬁt of kenshin and kidney biopsies depends
on whether early intervention can improve the prognosis
of IgA nephropathy. The Ministry of Health, Labour
and Welfare of Japan requires the Japanese Society of
Nephrology to demonstrate the efﬁcacy of kenshin; how-
ever, Japanese nephrologists are not currently able to do so.
H. Imai (&)  N. Miura
Division of Nephrology and Rheumatology,
Department of Internal Medicine,
Aichi Medical University School of Medicine,
Nagakute-cho, Aichi 480-1195, Japan
e-mail: imaihiro@aichi-med-u.ac.jp
123
Clin Exp Nephrol (2012) 16:195–201
DOI 10.1007/s10157-011-0552-8The desire of patients and their families
versus insufﬁcient clinical evidence
Since TSP was ﬁrst reported by Hotta et al. in 2001 [2], a
recent analysis revealed that 600 patients in Japan received
TSP in 2006. More than one thousand patients received
TSP in 2010. One year after TSP, 50% of patients achieved
clinical remission (CR), deﬁned as no urinary abnormali-
ties [3]. Many patients and their families, having discov-
ered information about the efﬁcacy of TSP through the
Internet or personal communications, visit the hospital to
seek TSP. Although many Japanese nephrologists know
that several international guidelines do not recommend
TSP for IgA nephropathy, they are challenged with making
decisions on which treatment is suitable for the patient,
while balancing the desire of patients and their families
against insufﬁcient clinical evidence.
A risk of overtreatment versus a lost ‘golden period’
Many Japanese nephrologists feel that patients with early-
stage or mild IgA nephropathy respond readily to TSP or
steroid pulse therapy. On the other hand, patients with
proteinuria [1.0 g/day and creatinine clearance (CCr)
\70 ml/min are resistant not only to TSP but also to oral
steroid therapy. The ‘golden period’ exists when patients
have proteinuria\1.0 g/day.
Preservation of kidney function versus induction
of clinical remission
The goal of many clinical studies is the preservation of
renal function. However, Hotta et al. emphasized that TSP
can induce CR and demonstrated that patients who respond
to TSP could maintain their kidney function. Some Japa-
nese nephrologists are shifting from a paradigm of pre-
serving kidney function to inducing CR.
What is the overall natural history of IgA nephropathy?
Chauveau and Droz [4] studied the natural history of IgA
nephropathy in 1993. In a series of 119 patients with
biopsy-proven IgA nephropathy from 1968 to 1972 at
Necker Hospital, 74 patients (44 men and 30 women)
received no therapy. Of this subset, 22 patients (29.7%)
showed spontaneous remission, deﬁned as no urinary
abnormalities and normal kidney function, 24 patients
(32.4%) had urinary abnormalities without aggravation of
kidney function, and 28 patients (37.8%) progressed to
end-stage renal failure during a 20-year observation period
(Table 1).
Do patients with mild or early-stage IgA nephropathy
recover or progress?
Szeto et al. reported on the natural history of mild or early-
stage IgA nephropathy in patients with proteinuria\0.4 g/
day over an observation period of 7 years [5]. About 40% of
these patients showed a progressive course—33% had pro-
teinuria increased to [1.0 g/day, and 7% had decreased
kidney function deﬁned as CCr \70 ml/min/1.73 m
2.
Another 42% of patients had persistent proteinuria and
hematuria; however, 14% of patients reached CR that the
authorsdeﬁnedasthedisappearanceofhematuria(Table 2).
Shen et al. also analyzed the natural history of IgA
nephropathy withisolatedmicroscopic hematuria,deﬁnedas
no detection of urinary protein by dipstick [6]. They com-
pared patients with no proteinuria (\0.03 g/day) and micro-
albuminuria (0.03–0.30 g/day): the CR rate (disappearance
ofhematuria)was22versus6%(p = 0.005),theincidenceof
increased proteinuria was 6 versus 42% (p\0.0001),
hypertensionwas12versus44%(p = 0.0001),andimpaired
kidney function [glomerular ﬁltration rate (GFR) \60 ml/
min/1.73 m
2] was 4 versus 29% (p = 0.0042), respectively.
They demonstrated that microalbuminuria was one of the
prognostic factors in IgA nephropathy with isolated micro-
scopic hematuria (Table 2).
Does oral prednisolone therapy improve the outcome
of IgA nephropathy?
In 1996, Kobayashi et al. [7] evaluated the efﬁcacy of oral
steroid therapy for patients with IgA nephropathy. Their
retrospective cohort study tracked the prognosis of 20
patients who received oral steroid therapy and 26 patients
who did not receive steroid therapy for 10 years. All
patients in both groups had persistent baseline proteinuria
ranging between 1.0 and 2.0 g/day. In the steroid therapy
group, 40 mg/day of prednisolone was administered for
8 weeks, which was then tapered to 30 mg/day for
8 weeks, 25 mg/day for 8 weeks, 20 mg/day for 8 weeks,
and 10–15 mg/day for 80 weeks. The total duration of
Table 1 A natural history of IgA nephropathy at Necker Hospital
Chauveau and
Droz
Observation period 20 years
Number of patients 74
Spontaneous remission 29.7%
Persistent urinary abnormalities without
aggravation of kidney function
32.4%
End-stage renal failure 37.8%
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123prednisolone therapy was 2 years, after which patients
were treated with only the same antiplatelet drugs that the
control group received. In the control group, patients had a
renal survival rate at 5 and 10 years of 84 and 34%,
respectively. On the other hand, in the steroid therapy
group, the renal survival rate at 5 and 10 years in patients
was 100 and 80%, respectively (compared to control group:
p\0.001). They concluded that patients with early-stage
IgA nephropathy, with proteinuria between 1.0 and 2.0 g/
day and CCr [70 ml/min, had a durable response to oral
steroid therapy at 10 years (Table 3).
Does methylprednisolone pulse therapy preserve kidney
function?
Pozzi et al. [8] demonstrated the efﬁcacy of steroid pulse
therapy for patients with IgA nephropathy with daily pro-
teinuria in the range of 1.0–3.5 g and serum creatinine
\1.5 mg/dl. In 86 patients with biopsy-proven IgA
nephropathy diagnosed between 1987 and 1995, 43 patients
were randomized to steroid pulse therapy and 43 to non-
steroid (antiplatelet) therapy. Patients in both groups were
balanced with respect to age (38 vs. 40), the presence of
hypertension (14/43 vs. 15/43), daily proteinuria (1.6–2.4
vs. 1.4–2.4 g/day), CCr (70–111 vs. 72–112 ml/min), and
percentage of glomerular sclerosis (0–25 vs. 5–26%); these
patients are similar to the patients in the study by Kobayashi
et al. Pozzi et al. deﬁned renal outcome as the primary
endpoint, measured as the doubling of baseline serum cre-
atinine, and the reduction of urinary protein as the sec-
ondary endpoint, but did not evaluate parameters of renal
function such as CCr or GFR or the renal survival rate. The
percentage of non-progressive patients at 10 years was 97%
in the steroid pulse therapy group and 53% in the control
group. Although they did not speciﬁcally evaluate CR,
approximately 10% of patients receiving steroid pulse
therapy reached CR. Pozzi et al. suggested that steroid pulse
therapy is efﬁcacious in patients with IgA nephropathy with
CCr [70 ml/min (mean 90 ml/min) and proteinuria
between 1.0 and 3.5 g/day (Table 3).
Does tonsillectomy stop the progression of renal
failure?
Rasche et al. [9] reported that tonsillectomy showed no
efﬁcacy in a retrospective cohort study in 1999. Of 55
patients diagnosed with IgA nephropathy from 1968 to
1994, 16 patients received tonsillectomy and 39 patients
did not. The patient characteristics were as follows: mean
age, 32 (range 23–34) versus 33 (28–34); presence of
hypertension, 14/16 versus 16/39; daily proteinuria[1.5 g,
9/16 versus 25/39; mean serum creatinine ± SD, 2.4 ± 2.8
versus 1.6 ± 0.9 mg/dl; serum creatinine[1.7 mg/dl, 4/16
versus 15/39. The CCr was estimated to be\70 ml/min, a
level below which Kobayashi et al. found oral steroid
therapy not to be efﬁcacious. The renal survival rates of
Table 2 The natural history
of patients with mild or
early-stage IgA nephropathy
Shen et al. Szeto et al.
Daily proteinuria \0.03 g [0.03,\0.3 g Total (\0.3 g) \0.4 g
Observation period 92 ± 28 months 84 (14–180) months
Number of patients 50 85 135 72
Disappearance of hematuria 22% 6% 12% 14%
Increased proteinuria ([1.0 g) 6% 42% 29% 33%
Hypertension 12% 44% 32% 19%
Decreased kidney function 4% 29% 20% 7%
Table 3 Oral steroid therapy
and intravenous steroid
pulse therapy
CCr creatinine clearance, ns not
signiﬁcant
Kobayashi et al. Pozzi et al.
Study design Retrospective cohort study Randomized controlled trial
Treatment groups Oral steroid versus control Steroid pulse versus control
Daily proteinuria 1.0–2.0 g 1.0–3.5 g
CCr 85 ± 14 versus 88 ± 13 70–111 ml/min (mean 91)
CCr (C70 ml/min) Renal survival rate: 100 versus
80% at 5 years (ns)
80 versus 34% at 10 years
(p\0.001)
Non-progression rate:
97 versus 53% at 10 years (p = 0.0003)
Urinary complete remission rate: *10%
in the steroid pulse group
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123both groups at 5 years were between 60% and 70% and at
10 years were between 40% and 60%, with no signiﬁcant
differences between both groups. They concluded that
tonsillectomy did not prevent a progressive course in
patients with IgA nephropathy (Table 4).
On the other hand, Xie et al. [10] demonstrated the
efﬁcacy of tonsillectomy with an observation period of
20 years. They analyzed the data from a retrospective
cohort study that included 48 patients who received
tonsillectomy and 70 patients who did not receive ton-
sillectomy. The mean age ± SD was 30 ± 11 versus
34 ± 12 years, daily proteinuria 0.91 ± 1.12 versus
1.09 ± 1.43 g, and serum creatinine was 1.07 ± 0.27
versus 1.07 ± 0.31 mg/dl. These patients correspond to an
earlier or milder stage than those in the study by Rasche
et al. The renal survival rates of the tonsillectomy and non-
tonsillectomy groups at 10 years were 98% and 89%,
respectively, with no statistically signiﬁcant difference;
however, the renal survival rates at 20 years were 90% and
63.8%, respectively (p\0.05). They summarized that
tonsillectomy improved renal survival in IgA nephropathy
patients 20 years later (Table 4).
In 2007, Chen et al. [11] investigated the efﬁcacy of
tonsillectomy in terms of long-term CR and renal survival
in Chinese patients with IgA nephropathy. They performed
a 130-month retrospective case-control study of 112
patients with idiopathic biopsy-proven IgA nephropathy
from 1983 to 1999. There were 54 patients who underwent
tonsillectomy and 58 patients who did not. The CR rate
was 46.3% in patients with tonsillectomy and 27.6% in
those without tonsillectomy during the follow-up period
that lasted a mean ± SD of 130 ± 50.3 months (range
60–276 months). The Kaplan–Meier analysis showed no
signiﬁcant difference in renal survival rates between
patients with and without tonsillectomy (p = 0.059). Since
the p value was 0.059 with an observation period of
15 years, differences in the renal survival rate with versus
without tonsillectomy may become signiﬁcant if the
observation period were extended to over 20 years
(Table 4).
Does TSP induce CR?
In 2001, Hotta et al. [2] proposed TSP as a new approach
that can induce CR in IgA nephropathy. They analyzed
329 patients with IgA nephropathy from 1977 to 1995.
The patient proﬁle was as follows: age (mean ± SD),
36.1 ± 12.8 years; daily proteinuria, 1.40 ± 1.09 g; serum
creatinine, 1.14 ± 0.48 mg/dl. There was a correlation
between serum creatinine levels and urinary remission
rates. In patients with serum creatinine \0.8 mg/dl, the
urinary complete remission rate was 55% in men and 65%
in women. In patients with serum creatinine between 0.9
and 1.0 mg/dl, it was 55% in both men and women, and in
patients with serum creatinine between 1.1 and 1.3 mg/dl,
it was 50% in men and 30% in women. Male and female
patients with serum creatinine [1.4 mg/dl had a urinary
complete remission rate of approximately 20%. These
results suggest that patients with serum creatinine
[1.4 mg/dl are resistant to several types of therapy,
including steroid therapy and TSP. In a Cox regression
analysis with 13 variables, serum creatinine \1.3 mg/dl,
daily proteinuria between 0.5 and 1.5 g, histological score
(the index of glomerular lesion, calculated by the degree of
mesangial proliferation and sclerosis)\2.00, steroid pulse
therapy, and tonsillectomy were identiﬁed as prognostic
factors for urinary complete remission. A comparison of
the CR rate with TSP and steroid therapy found TSP to be
superior (59.7 vs. 35.3%; p\0.01) [8] (Table 5).
Table 4 A retrospective cohort study of tonsillectomy
Rasche et al. Xie et al. Chen et al.
Treatment groups Tonsillectomy versus control Tonsillectomy versus control Tonsillectomy versus control
Daily proteinuria ([1.5 g)
9/16 versus 25/39
0.91 ± 1.12 versus 1.09 ± 1.43 0.973 ± 0.924 versus 1.17 ± 1.02
([1.0 g) 19/54 versus 23/58
sCr 2.4 ± 2.8 versus 1.6 ± 0.9 1.07 ± 0.27 versus 1.07 ± 0.31 1.08 ± 0.33 versus 1.07 ± 0.275
CCr (C70 ml/min) Not available Renal survival rate: 98 versus 89%
at 10 years (ns)
90 versus 63.8% at 20 years
(efﬁcacy at 20 years; p\0.05)
CR rate: 46.3 versus 27.5% (p = 0.04)
Relapse rate: 38.9 versus 48.3%
(p = 0.317)
Not improved rate: 16.7 versus 34.5%
(p = 0.031)
ESRD at less than 15 years: 3.7 versus
12.1% (p = 0.059)
CCr (\70 ml/min) Renal survival rate: 40% and
60% at 10 years (ns)
Not available Not available
sCr serum creatinine, CCr creatinine clearance, CR clinical remission, ESRD end-stage renal disease, ns not signiﬁcant
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123In 2002, Sato et al. [12] evaluated the efﬁcacy and
limitations of TSP in patients with advanced IgA
nephropathy. TSP is superior to steroid therapy or anti-
platelet therapy in terms of 8-year renal survival rates (82.8
vs. 51.0 vs. 45.1%, respectively); however, there was no
signiﬁcant difference among patients whose baseline serum
creatinine was [2.0 mg/dl. They recommended initiating
TSP before serum creatinine reaches 2.0 mg/dl (Table 5).
In 2010, Kawaguchi et al. [13] retrospectively analyzed
388 patients diagnosed with IgA nephropathy by renal
biopsy between 1987 and 2000 who presented with
hematuria and minimal proteinuria (\0.5 g/day) at base-
line. Patients treated with TSP had a signiﬁcantly higher
rate of CR than patients who were not treated with ton-
sillectomy or pulsed steroids in both an unadjusted Cox
model [hazard ratio (HR) 5.51; 95% conﬁdence interval
(CI) 3.33–9.12; p\0.001] and one adjusted for age, sex,
estimated GFR, index of glomerular lesion, systolic blood
pressure, immunoglobulin A, 24-h urinary protein excre-
tion, urinary red blood cells, comorbidities, and medication
(HR 4.65; 95% CI 2.43–8.88; p\0.001). TSP signiﬁcantly
increased the probability of CR in IgA nephropathy
patients with minimal proteinuria (Table 5).
Do all patients with IgA nephropathy respond to TSP?
Miura et al. [3] evaluated the efﬁcacy of TSP in a multi-
center retrospective cohort study. After collecting data
from many hospitals in Japan, they ﬁrst identiﬁed groups
with higher and lower CR rates and compared patient
characteristics between the two groups. There was a
Table 5 A retrospective cohort study of tonsillectomy plus steroid pulse (TSP) therapy
Hotta et al. Miura et al.
Study design Retrospective cohort study Multicenter retrospective study
Patients’ background Daily proteinuria: mean ± SD: 1.38 ± 1.17 g
sCr: 0.96 ± 0.22 mg/dl
CCr ([70 ml/min) TSP versus steroid: CR rate: 59.7 versus 35.3%; p\0.01 CR rate: 54.1%
CR versus non-CR:
Years from diagnosis until TSP therapy: mean ± SD
5.3 ± 5.2 versus 6.9 ± 6.8 (p = 0.02)
Daily proteinuria 0.8 ± 0.8 versus 1.5 ± 1.6 (p\0.0001)
sCr 0.87 ± 0.34 versus 0.99 ± 0.40 (p = 0.006)
CCr (\70 ml/min) Sato et al.
Retrospective cohort study
TSP versus steroid versus control
Daily proteinuria: mean ± SD:
2.2 ± 1.9 versus 1.9 ± 0.9 versus 0.9 ± 0.6
CCr: 45.0 ± 15.1 versus 44.4 ± 14.9 versus 48.6 ± 19.7
Renal survival rate at 8 years:
82.8 versus 51.0 versus 45.1%: p = 0.017
(No signiﬁcant difference in patients with sCr[2.0 mg/dl)
Not available
sCr serum creatinine, CCr creatinine clearance, CR clinical remission
Table 6 Prospective controlled trials
Komatsu et al. Miyazaki et al.
Study design Prospective controlled trial Randomized controlled trial
Treatment groups TSP versus steroid pulse TSP (40 patients) versus steroid pulse (40 patients)
Daily proteinuria (mean ± SD) 1.06 ± 1.01 versus 1.41 ± 1.05 Between 1.0 and 3.5 g
sCr 0.72 ± 0.29 versus 0.84 ± 0.30 sCr\1.5 mg/dl
CCr ([70 ml/min) CR rate:
21/34 (61.8%) versus 3/17 (17.6%)
(p\0.001)
Forthcoming
TSP tonsillectomy plus steroid pulse, RCT randomized controlled trial, sCr serum creatinine, CCr creatinine clearance, CR clinical remission
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123signiﬁcant difference in age at onset (p = 0.05), daily
proteinuria (p = 0.02), total protein (p = 0.02), and path-
ological grade (p = 0.009) between the higher CR rate
group and the lower CR rate group. In the 303 patients
included in their study, 164 (54.1%) patients reached CR
1 year after TSP. The comparison between patients who
reached CR and those who did not achieve CR revealed
signiﬁcant differences in the number of years from diag-
nosis until TSP (p = 0.02), daily proteinuria (p\0.0001),
serum creatinine (p = 0.006), and pathological grade
(p = 0.0006). Miura et al. showed that TSP was effective
for patients with early-stage disease if performed within
5 years at onset, with daily proteinuria \1.1 g and serum
creatinine\1.5 mg/dl (Table 5).
Do prospective controlled studies conﬁrm the efﬁcacy
of TSP?
Komatsu et al. [14] reported the results of a prospective trial
of TSP in 2008. They compared the data on patients treated
with TSP (n = 35) and patients who received only steroid
pulse therapy (n = 20). The mean daily proteinuria ± SD
was 1.06 ± 1.01 versus 1.41 ± 1.05 g, and mean serum
creatinine ± SD was 0.72 ± 0.29 versus 0.84 ± 0.30 mg/
dl, respectively. The CR rate at 24 months was 61.8 versus
17.6% (p\0.001). The authors concluded that TSP can
induce CR in patients with IgA nephropathy with daily
proteinuria of approximately 1.0 g and serum creatinine
\1.1 mg/dl. However, their study was limited since it was
not randomized, and the patients’ baseline data differed
slightly between the two treatment groups (Table 6).
Miyazaki et al. [15] performed a randomized controlled
trial (RCT) of TSP in Japan, with the following inclusion
criteria: daily proteinuria between 1.0 and 3.5 g, serum
creatinine \1.5 mg/dl, and chronic tonsillitis. Although
detailed data will be available in the near future, pre-
liminary data from this trial suggest that TSP is a promising
treatment for inducing CR of IgA nephropathy, and might
become ﬁrst-line treatment for IgA nephropathy (Table 6).
Perspectives on the treatment of IgA nephropathy
After the details of the RCT on TSP are released, several
clinical questions will emerge. Which patients with IgA
nephropathy are ideal candidates for TSP? At what level of
daily urinary protein is a kidney biopsy indicated? Does
early intervention really improve prognosis? Can IgA
nephropathy recur after TSP? We have to answer these
questions.
In order to obtain clinical evidence within a short 5-year
period, we propose a clinical trial enrolling patients with
daily proteinuria \1.0 g and GFR or CCr [90 ml/min
whose primary endpoints are the CR rate and the propor-
tion of patients whose GFR or CCr decrease to B70 ml/min
(rate of decline in renal function). Patients should be
divided randomly into three groups: antiplatelet drugs,
steroid pulse therapy according to the protocol in Pozzi
et al., and TSP according to the protocol of Hotta et al. This
trial should be open to international investigators. This
proposed RCT is essential for studying TSP for early stages
of IgA nephropathy. Alternatively, prospective cohort
studies are needed to evaluate the renal survival rate after
20 years. Finally, as the recurrence of IgA nephropathy
after renal transplantation is a signiﬁcant issue, RCTs
involving TSP before transplantation will provide infor-
mation on recurrence of IgA nephropathy. The results of
the current RCT in Japan will propel us into a new era of
treatment for IgA nephropathy.
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